Genmab A/S (FRA:GE91)

Market Cap	16.68B +24.5%
Revenue (ttm)	3.28B +29.6%
Net Income	1.35B +125.1%
EPS	21.39 +132.4%
Shares Out	n/a
PE Ratio	12.36
Forward PE	23.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	28.80
Previous Close	28.00
Day's Range	28.80 - 28.80
52-Week Range	15.90 - 29.80
Beta	n/a
RSI	48.80
Earnings Date	Feb 17, 2026

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 2,681
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GE91

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial numbers in USD